Sanofi to Offer All Sanofi Insulin for $35 a Month, Regardless of Income, Insurance Type

Sanofi will offer a 30-day supply of any combination, type or quantity of their insulin for $35 to all patients with a valid prescription, regardless of income or insurance status, starting January 1, 2026, according to a recent company news release. This fixed monthly rate will be available through their Insulins Valyou Savings Program, which was originally established for patients without health insurance.

Insulin brands covered include:

• Admelog (insulin lispro)
• Apidra (insulin glulisine)
• Lantus(insulin glargine)
• Merilog (insulin aspart-szjj)
• Soliqua100/33 (insulin glargine and lixisenatide)
• Toujeo (insulin glargine)

"Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter,” Adam Gluck, head of U.S. corporate affairs at Sanofi, said in the news release. "By expanding our Insulins Valyou Savings Program, we're taking concrete action to address a critical healthcare issue for millions of Americans living with diabetes. We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines."

This announcement is part of a growing trend of direct-to-consumer discount programs offered by insulin manufacturers. In addition to President Trump’s April executive order to cap prices at $35 a month for Medicare Part D enrollees, Lilly also offers a $35 insulin program, and Novo Nordisk offers multiple discounts, including a $25 vial offer redeemable at Walmart under the name ReliOn.

However, for privately insured diabetes patients, copay caps vary by state and eligibility. For example, there is a $100 copay cap for diabetes patients in Vermont, but in New York, there is $0 cost sharing.

More than 37 million Americans are diabetic, including approximately 8.4 million diabetics who rely on insulin to survive.

Type 1 diabetes is an autoimmune disease in which a person’s immune system destroys insulin producing cells in the pancreas. As a result, type 1 diabetes patients rely on insulin indefinitely.

Type 2 diabetes can be caused by genetics, lifestyle or age. Depending on severity, these patients may also rely on insulin, but in some cases, such as weight loss, the disease can be reversed.

Insulin costs up to 10 times more in the United States than in other countries, leading as many as 1 in 5 patients to ration their insulin, according to a study from Harvard Medical School and Hunter College.

In the United States, the cost of diabetes medical costs rose 35% from 2012 to 2022, according to an analysis by the American Diabetes Association. In 2022, the average healthcare expenditure for diabetes was $412.9 billion. A majority (67%) of services were for patients at least 65 years old. Diabetes patients incurred an average of $19,736 annually in health expenses, with $12,022 attributable to diabetes.

"Diabetes management requires consistent access to medication, and financial barriers can lead to rationing or skipping doses, which can have serious health consequences," Olivier Bogillot, head of general medicines, North America, at Sanofi, also said in the news release. "This program expansion emphasizes our continued support for America's diabetes community."

Qualified middle- or low-income patients who have an urgent need for insulin may be able to receive a free, one-time 30-day supply through the Sanofi Temporary Access Program.

Interested patients can enroll at Sanofi Patient Connection or by calling 1-888-847-4877.